Please login to the form below

Not currently logged in
Email:
Password:

Teva completes Cephalon purchase

Teva Pharmaceutical has acquired US-based biopharmaceutical company Cephalon for about $6.8bn following approval from the European Union

Teva Pharmaceutical has acquired US-based biopharmaceutical company Cephalon for about $6.8bn following approval from the European Union (EU).

The EU had demanded that Teva sell off its generic version of Cephalon's narcolepsy drug, Provigil (modafinil), to enable another company to own a competitor product.

Cephalon is now a wholly owned subsidiary of Teva, with Cephalon to receive $81.50 per share of common stock.

Teva said the combined company is to have a presence in over 60 countries. As individual companies, the combined revenue of Teva and Cephalon for the period July 2010 to June 2011 was around $20bn.

Shlomo Yanai, president and CEO of Teva, said the purchase was part of the Israel-based company's attempt to build its branded pharmaceuticals business through diversification and expansion of its product portfolio and pipeline.

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics